STOCK TITAN

Schedule 13G/A: Squadron Reports Material Holdings in RLMD

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Schedule 13G/A filed for Relmada Therapeutics (RLMD) discloses beneficial ownership stakes held by Squadron-related filers. Squadron Master Fund LP reports shared beneficial ownership of 2,914,495 shares representing 8.8% of the outstanding common stock. Squadron Capital Management LLC and William Blank each report shared beneficial ownership of 3,298,500 shares, representing 9.9% of the class. The filing clarifies that Squadron Capital Management serves as adviser to funds that hold these shares and that Mr. Blank may be deemed to have investment and voting discretion, while expressly disclaiming beneficial ownership under Rule 13d-4. The ownership percentages are calculated using an issuer-stated share count of 33,191,622 shares outstanding.

Positive

  • Material disclosure of sizeable holdings: Squadron Capital Management reports 3,298,500 shares (9.9%) and Squadron Master Fund reports 2,914,495 shares (8.8%).
  • Passive intent stated: The filers include a Rule 13d-4 disclaimer and a certification indicating the positions are not held to change or influence control.

Negative

  • None.

Insights

TL;DR: Squadron-affiliated entities report material stakes in RLMD (8.8% and 9.9%), a notable concentrated ownership disclosure for investors.

This Schedule 13G/A signals that investment funds advised by Squadron Capital Management hold sizeable, non-control positions in Relmada Therapeutics. The adviser-level and individual-level reporting of 3,298,500 shares (9.9%) and the fund-level 2,914,495 shares (8.8%) are material because they exceed the 5% disclosure threshold and can affect float and shareholder composition. The filing includes a standard Rule 13d-4 disclaimer, indicating passive intent rather than an explicit plan to influence control. For analysts, the key implications are concentrated ownership and advisory alignment rather than an activist posture.

TL;DR: Disclosure shows substantial shared voting/dispositive power but an explicit disclaimer of beneficial ownership under Rule 13d-4.

The report identifies shared voting and dispositive power for the reported shares rather than sole power, and it contains the customary certification that the positions were not acquired to change or influence issuer control. That combination—material holdings with a passive filing status—suggests governance implications are limited at filing time, though concentrated stakes merit monitoring for future engagement. The filing properly aligns with Schedule 13G reporting conventions for passive investors and advisers.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Squadron Master Fund LP
Signature:/s/ Matt Sesterhenn
Name/Title:Partner, Squadron Partners LLC, its General Partner
Date:08/14/2025
Squadron Capital Management LLC
Signature:/s/ Matt Sesterhenn
Name/Title:Partner
Date:08/14/2025
William Blank
Signature:/s/ William Blank
Name/Title:William Blank
Date:08/14/2025

FAQ

What stake does Squadron Capital Management report in RLMD?

Squadron Capital Management reports shared beneficial ownership of 3,298,500 shares, representing 9.9% of RLMD's outstanding common stock.

How many shares does Squadron Master Fund LP hold in RLMD?

Squadron Master Fund LP reports shared beneficial ownership of 2,914,495 shares, representing 8.8% of the class.

Does the filing indicate an intent to influence control of Relmada Therapeutics (RLMD)?

No. The filing includes a certification and a Rule 13d-4 disclaimer stating the securities were not acquired to change or influence control and the filers disclaim beneficial ownership where applicable.

On what share count are the ownership percentages based?

Percentages are based on an issuer-stated outstanding share count of 33,191,622 shares as represented by the issuer.

Who is William Blank in relation to these holdings?

William Blank is reported as a partner with shared voting and dispositive power over 3,298,500 shares (9.9%), and is associated with Squadron Capital Management.
Relmada Therapeutics Inc

NASDAQ:RLMD

RLMD Rankings

RLMD Latest News

RLMD Latest SEC Filings

RLMD Stock Data

312.40M
65.37M
Biotechnology
Pharmaceutical Preparations
Link
United States
CORAL GABLES